Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 69


Racial Differences in Age-Related Variations of Testosterone Levels Among US Males: Potential Implications for Prostate Cancer and Personalized Medication.

Hu H, Odedina FT, Reams RR, Lissaker CT, Xu X.

J Racial Ethn Health Disparities. 2015 Mar;2(1):69-76. doi: 10.1007/s40615-014-0049-8. Epub 2014 Sep 11.


[The focus and prospect of prostate cancer research].

Li H, Dong D.

Zhonghua Wai Ke Za Zhi. 2015 Apr;53(4):253-6. Review. Chinese.


DOC-2/DAB2 interacting protein status in high-risk prostate cancer correlates with outcome for patients treated with radiation therapy.

Jacobs C, Tumati V, Kapur P, Yan J, Hong D, Bhuiyan M, Xie XJ, Pistenmaa D, Yu L, Hsieh JT, Saha D, Kim DW.

Int J Radiat Oncol Biol Phys. 2014 Jul 15;89(4):729-35. doi: 10.1016/j.ijrobp.2014.03.035. Epub 2014 May 24.


Testosterone replacement therapy following the diagnosis of prostate cancer: outcomes and utilization trends.

Kaplan AL, Trinh QD, Sun M, Carter SC, Nguyen PL, Shih YT, Marks LS, Hu JC.

J Sex Med. 2014 Apr;11(4):1063-1070. doi: 10.1111/jsm.12429. Epub 2014 Jan 21.


Prostate-specific antigen at 4 to 5 years after low-dose-rate prostate brachytherapy is a strong predictor of disease-free survival.

Lo AC, Morris WJ, Lapointe V, Hamm J, Keyes M, Pickles T, McKenzie M, Spadinger I.

Int J Radiat Oncol Biol Phys. 2014 Jan 1;88(1):87-93. doi: 10.1016/j.ijrobp.2013.10.010.


Gleason pattern 5 is the strongest pathologic predictor of recurrence, metastasis, and prostate cancer-specific death in patients receiving salvage radiation therapy following radical prostatectomy.

Jackson W, Hamstra DA, Johnson S, Zhou J, Foster B, Foster C, Li D, Song Y, Palapattu GS, Kunju LP, Mehra R, Feng FY.

Cancer. 2013 Sep 15;119(18):3287-94. doi: 10.1002/cncr.28215. Epub 2013 Jul 2.


Advances in the treatment of metastatic prostate cancer.

Chowdhury S, Kirby R.

Practitioner. 2013 Apr;257(1760):15-8, 2.


Use of testosterone replacement therapy in the United States and its effect on subsequent prostate cancer outcomes.

Kaplan AL, Hu JC.

Urology. 2013 Aug;82(2):321-6. doi: 10.1016/j.urology.2013.03.049. Epub 2013 May 24.


Current role of neoadjuvant and adjuvant systemic therapy for high-risk localized prostate cancer.

Dorff TB, Glode LM.

Curr Opin Urol. 2013 Jul;23(4):366-71. doi: 10.1097/MOU.0b013e328361d467. Review.


Death from high-risk prostate cancer versus cardiovascular mortality with hormonal therapy: a decision analysis.

Lester-Coll NH, Goldhaber SZ, Sher DJ, D'Amico AV.

Cancer. 2013 May 15;119(10):1808-15. doi: 10.1002/cncr.27980. Epub 2013 Feb 7. Erratum in: Cancer. 2013 Jun 15;119(12):2358. Dosage error in article text.


Intermittent androgen suppression for rising PSA level after radiotherapy.

Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L.

N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546. Erratum in: N Engl J Med. 2012 Dec 6;367(23):2262.


The prognostic value of expression of HIF1α, EGFR and VEGF-A, in localized prostate cancer for intermediate- and high-risk patients treated with radiation therapy with or without androgen deprivation therapy.

Weber DC, Tille JC, Combescure C, Egger JF, Laouiti M, Hammad K, Granger P, Rubbia-Brandt L, Miralbell R.

Radiat Oncol. 2012 Apr 30;7:66. doi: 10.1186/1748-717X-7-66.


Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspective.

Namiki M, Ueno S, Kitagawa Y, Fukagai T, Akaza H.

Asian J Androl. 2012 May;14(3):451-7. doi: 10.1038/aja.2011.121. Epub 2012 Mar 26. Review.


Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term.

Wilcox C, Kautto A, Steigler A, Denham JW.

Oncology. 2012;82(1):56-8. doi: 10.1159/000334999. Epub 2012 Feb 4.


Androgen deprivation therapy in prostate cancer: focusing on sexual side effects.

Corona G, Gacci M, Baldi E, Mancina R, Forti G, Maggi M.

J Sex Med. 2012 Mar;9(3):887-902. doi: 10.1111/j.1743-6109.2011.02590.x. Epub 2012 Jan 16. Review.


Allelic loss of the loci containing the androgen synthesis gene, StAR, is prognostic for relapse in intermediate-risk prostate cancer.

Locke JA, Zafarana G, Malloff CA, Lam WL, Sykes J, Pintilie M, Ramnarine VR, Meng A, Ahmed O, Jurisica I, Guns ET, van der Kwast T, Milosevic M, Bristow RG.

Prostate. 2012 Sep 1;72(12):1295-305. doi: 10.1002/pros.22478. Epub 2011 Dec 27.


Surrogate endpoints for prostate cancer-specific mortality after radiotherapy and androgen suppression therapy in men with localised or locally advanced prostate cancer: an analysis of two randomised trials.

D'Amico AV, Chen MH, de Castro M, Loffredo M, Lamb DS, Steigler A, Kantoff PW, Denham JW.

Lancet Oncol. 2012 Feb;13(2):189-95. doi: 10.1016/S1470-2045(11)70295-9. Epub 2011 Nov 21.


Biochemical control with radiotherapy improves overall survival in intermediate and high-risk prostate cancer patients who have an estimated 10-year overall survival of >90%.

Herbert C, Liu M, Tyldesley S, Morris WJ, Joffres M, Khaira M, Kwan W, Moiseenko V, Pickles T.

Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):22-7. doi: 10.1016/j.ijrobp.2011.05.076. Epub 2011 Nov 11.


Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer.

Boorjian SA, Karnes RJ, Viterbo R, Rangel LJ, Bergstralh EJ, Horwitz EM, Blute ML, Buyyounouski MK.

Cancer. 2011 Jul 1;117(13):2883-91. doi: 10.1002/cncr.25900. Epub 2011 Jan 10.


Pelvic nodal radiotherapy in patients with unfavorable intermediate and high-risk prostate cancer: evidence, rationale, and future directions.

Morikawa LK, Roach M 3rd.

Int J Radiat Oncol Biol Phys. 2011 May 1;80(1):6-16. doi: 10.1016/j.ijrobp.2010.11.074. Review.


Supplemental Content

Loading ...
Support Center